Imatinib Mesylate Tablet, Film Coated
Product Images NDC 31722-296

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 31722-296). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib100mg90scontainer (Imatinib100mg90scontainer)

This is a description of Imatinib Mesylate Tablets, with each film-coated tablet containing 119.50 mg of imatinib mesylate equivalent to 100 mg of imatinib free base. The dosage information is provided in the Prescribing Information. It is recommended to store the tablets at 20°C to 25°C and to protect them from moisture. The text also includes the U.S. contact number for inquiries and the manufacturing details for Camber Pharmaceuticals, Inc. The tablets are dispensed in a tight container and must be kept out of reach of children. Additionally, the manufacturing details indicate that they are produced by Hetero Labs Limited in India.*

FDA Label Image

Imatinib400mg30scontainer (Imatinib400mg30scontainer)

This text is a description of Imatinib Mesylate tablets manufactured by Camber Pharmaceuticals. Each film-coated tablet contains 478 mg of imatinib mesylate, which is equivalent to 400 mg of imatinib free base. The recommended dosage and storage conditions are provided. The medication should be kept at temperatures between 20°C to 25°C with excursions permitted between 15°C to 30°C. It is essential to protect the tablets from moisture and store them in a tight container. The contact information for Camber Pharmaceuticals and the manufacturing details are also mentioned.*

FDA Label Image

Imatinibcamberlogo (Imatinibcamberlogo)

FDA Label Image

Imatinibfigure1 (Imatinibfigure1)

This is a statistical report on the progression of patients on Imatinib Mesylate treatment. It provides data on the number of patients with progression, those censored at discontinuation, and at last follow-up. It also includes the hazard ratio and Log-rank Test results, showing significant differences. The report covers a time span of months since randomization.*

FDA Label Image

Imatinibfigure2 (Imatinibfigure2)

This data appears to be related to a clinical study evaluating the efficacy of Imatinib Mesylate in patients with progression to accelerated phase (AP) or blast crisis (BC) of the disease. The analysis includes the number of patients in each group, hazard ratio, log-rank test results, and the timeline in months since randomization. The study suggests a significant difference in progression-free survival between the Imatinib Mesylate arm and the IFN+Ara-C arm.*

FDA Label Image

Imatinibfigure3 (Imatinibfigure3)

FDA Label Image

Imatinibfigure4 (Imatinibfigure4)

FDA Label Image

Imatinibfigure5 (Imatinibfigure5)

This is information on the probability of the overall survival, with a P value of 0.0187 and a Hazard ratio of 0.45. The survival data is presented in months, with recorded events and censored observations. The data provided includes survival times ranging from 0 to 1980 months and corresponding risk percentages for different time intervals.*

FDA Label Image

Imatinibstructure (Imatinibstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.